Monoamine Oxidase-B Inhibition in Alzheimer's Disease

Author： Riederer P.   Danielczyk W.   Grunblatt E.  

Publisher： Elsevier

ISSN： 0161-813X

Source： Neurotoxicology, Vol.25, Iss.1, 2004-01, pp. : 271-277

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Monoamine Oxidase B Inhibitors in Parkinson's Disease

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease

By  

Current Topics in Medicinal Chemistry, Vol. 13, Iss. 14, 2013-07 ,pp. : 1692-1706

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of monoamine oxidase B inhibition by fluoxetine (Prozac): An in vitro and in vivo study

By Mukherjee J.   Yang Z.-Y.  

European Journal of Pharmacology, Vol. 337, Iss. 1, 1997-10 ,pp. : 111-114

Elsevier

Access to resources Recommend Favorite

Monoamine oxidase A and B inhibitors

By Jegham S.   George P.  

Expert Opinion on Therapeutic Patents, Vol. 8, Iss. 9, 1998-09 ,pp. : 1143-1150

Informa Healthcare

Access to resources Recommend Favorite

The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

By Elmer Lawrence W   Bertoni John M  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 16, 2008-11 ,pp. : 2759-2772

Informa Healthcare

Access to resources Recommend Favorite